FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlvotech
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALVO
Alvotech Stock AnalysisComprehensive stock analysis for Alvotech (ALVO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALVO
ALVO
Alvotech
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALVO
  1. Home
  2. Stocks
  3. Alvotech

Alvotech

🇺🇸ALVO•NASDAQ

Alvotech

🇺🇸ALVO•NASDAQ
Market cap
$1.62B

Your view on ALVO

Mkt Cap
$1.62B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Alvotech

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Linda Jonsdottir
Headquarters
IS
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Linda Jonsdottir
Headquarters
IS
Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product.

The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Alvotech. Starting points for Alvotech: EPS -$0.76, beta 0.18 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Alvotech. Trailing twelve-month EPS for Alvotech stands at -$0.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$8.75

average of 4 firms, last 12 months

 

$8.75

Low $8.00

Median $8.50

High $10.00

 

Analyst Ratings

Buy5 ratings
  • Strong Buy0
  • Buy3
  • Hold2
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.17−$0.01−$0.09$0.25
Low estimate$0.13−$0.01−$0.17$0.12
High estimate$0.21−$0.01−$0.03$0.38
No. of analysts3144
Year-ago EPS−$0.371−$0.091$0.101—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$293.10M$171.20M$590.82M$737.01M
Low estimate$280.25M$167.67M$541.05M$690.71M
High estimate$305.96M$174.73M$638.69M$783.31M
No. of analysts1144
Year-ago revenue$166.36M$105.86M$586.32M—
Growth+76.2%+61.7%+0.8%—
Recent analyst actions15 rating and price-target changes, latest Nov 10, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Alvotech. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALVO20 companies · 8 funds
Compare ALVO with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AMGNAmgen Inc.HealthcareDrug Manufacturers - General$240.1B
AMPHAmphastar Pharmaceuticals, Inc.HealthcareDrug Manufacturers - Specialty & Generic$1.3B
AMRXAmneal Pharmaceuticals, Inc.HealthcareDrug Manufacturers - Specialty & Generic$7.6B
BIIBBiogen Inc.HealthcareDrug Manufacturers - General$37.2B
COLLCollegium Pharmaceutical, Inc.HealthcareDrug Manufacturers - Specialty & Generic$805.8M
ETONEton Pharmaceuticals, Inc.HealthcareDrug Manufacturers - Specialty & Generic$1.8B
HROWHarrow Health, Inc.HealthcareDrug Manufacturers - Specialty & Generic$1.2B
OGNOrganon & Co.HealthcareDrug Manufacturers - General$3.7B
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
CRFTFBC Craft Supply Co. Ltd.HealthcareOTC$23
CRLBFCresco Labs Inc.HealthcareOTC$350.4M
CRONCronos Group Inc.HealthcareNASDAQ$1.2B
CRON.TOCronos Group Inc.HealthcareTSX$1.7B
CRYMCryomass Technologies Inc.HealthcareOTC$47,432
CSTFCuraScientific CorpHealthcareOTC$377,345
CSWYFChina Shineway Pharmaceutical Group LimitedHealthcareOTC$758.4M
CSWYYChina Shineway Pharmaceutical Group LimitedHealthcareOTC$36.4M
CURA.TOCuraleaf Holdings, Inc.HealthcareTSX$2.7B
CURLFCuraleaf Holdings, Inc.HealthcareOTC$1.9B
CVGR.CNCity View Green Holdings Inc.HealthcareCNQ$3.7M
CVGRFCity View Green Holdings Inc.HealthcareOTC$1.2M
ETFs holding Alvotech
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VWOVanguard FTSE Emerging Markets ETF$125.4B in assets0.01%
IBBiShares Biotechnology ETF$11.1B in assets0.05%
VEUVanguard FTSE All-World ex-US ETF$68.1B in assets0.00%
IBBQInvesco Nasdaq Biotechnology ETF$130M in assets0.10%
PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.01%
VEE.TOVanguard FTSE Emerging Markets All Cap Index ETF$4.4B in assets0.01%
VSGXVanguard ESG International Stock ETF$6.7B in assets0.00%

Largest holders first, then the funds most concentrated in ALVO.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Alvotech, and how their positions are changing. At a $1.62B market value, institutional positions materially move Alvotech's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Alvotech. Coverage tracks Alvotech within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Alvotech.

ALVO AnalysisWeak
Past
1
Growth
5
Health
1
Profit
1
Value
1

News

Latest Market News